At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 24 enrolled
Drug / intervention
Gefapixant +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Parallel, Double-Blind Study to Assess the Efficacy and Tolerability of AF-219 in Subjects With Refractory Chronic Cough
Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)·interventional·Posted Nov 24, 2015·Updated Nov 25, 2019
In Brief
A Phase 2 clinical trial evaluating Gefapixant and Placebo (for gefapixant) for Refractory Chronic Cough. Completed, enrolled 24 participants across 10 sites.
Detailed Summary
This was an 8-week randomized, parallel, double-blind, placebo-controlled study of gefapixant (AF-219) in participants with refractory chronic cough.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRefractory Chronic Cough
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedNov 2015
Enrollment StartDec 2015
Primary CompletionMay 2016
Study CompletionMay 2016
TodayJul 2026
First PostedNov 24, 2015
Enrollment StartDec 17, 2015
Primary CompletionMay 4, 2016
Study CompletionMay 18, 2016
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 10.6 years ago
Interventions
Gefapixantdrug
Gefapixant tablets administered by mouth twice daily for 8 weeks
Placebo (for gefapixant)drug
Matching placebo to gefapixant tablets administered by mouth twice daily for 8 weeks